Gratus Capital LLC bought a new stake in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 45,820 shares of the biopharmaceutical company’s stock, valued at approximately $1,613,000.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Stelac Advisory Services LLC acquired a new stake in shares of Pfizer during the second quarter worth $110,000. Commonwealth Financial Services LLC boosted its stake in shares of Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 210 shares in the last quarter. Catamount Wealth Management boosted its stake in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares in the last quarter. Stuart Chaussee & Associates Inc. boosted its stake in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 2,125 shares in the last quarter. Finally, Jag Capital Management LLC acquired a new stake in shares of Pfizer during the second quarter worth $202,000. Institutional investors and hedge funds own 69.65% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded down 1.81% during midday trading on Monday, hitting $33.64. 29,509,548 shares of the company traded hands. The company has a market cap of $204.05 billion, a PE ratio of 29.82 and a beta of 0.87. Pfizer Inc. has a 12-month low of $28.25 and a 12-month high of $37.39. The stock has a 50 day moving average price of $34.68 and a 200-day moving average price of $33.90.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The company earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. During the same period in the prior year, the company earned $0.56 EPS. Pfizer’s revenue was up 10.9% on a year-over-year basis. Analysts expect that Pfizer Inc. will post $2.46 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be issued a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a yield of 3.57%. The ex-dividend date is Tuesday, November 8th. Pfizer’s payout ratio is 95.24%.
A number of analysts recently weighed in on PFE shares. TheStreet upgraded shares of Pfizer from a “hold” rating to a “strong-buy” rating in a research note on Friday, June 3rd. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $36.89 price target for the company in a research note on Tuesday, June 7th. Jefferies Group reiterated a “buy” rating and set a $42.00 price target (up previously from $41.00) on shares of Pfizer in a research note on Tuesday, June 14th. Deutsche Bank AG restated a “buy” rating on shares of Pfizer in a research note on Wednesday, June 15th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $54.00 target price on shares of Pfizer in a research note on Monday, June 27th. Ten equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Pfizer currently has an average rating of “Buy” and an average price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.